CD274 and hepatocellular carcinoma: Currently, targeted PD-1/PD-L1 inhibitors have been ratified for the treatment of hepatocellular carcinoma, renal cancer, and advanced non-small-cell lung cancer, and atezolizumab is the first PD-L1 antibody ratified for advanced TNBC.